Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ.

Transl Oncol. 2011 Apr 1;4(2):59-70.

2.

Janus kinase 2 inhibitors in myeloproliferative disorders.

Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.

Expert Opin Investig Drugs. 2011 Jan;20(1):41-59. doi: 10.1517/13543784.2011.538382. Epub 2010 Dec 4. Review.

PMID:
21128825
3.

DNA damage-mediated induction of a chemoresistant niche.

Gilbert LA, Hemann MT.

Cell. 2010 Oct 29;143(3):355-66. doi: 10.1016/j.cell.2010.09.043.

4.

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

D'Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M, Zakowski MF.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):476-80. doi: 10.1016/j.jtcvs.2010.08.026. Epub 2010 Oct 8.

5.

Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation.

Leslie K, Gao SP, Berishaj M, Podsypanina K, Ho H, Ivashkiv L, Bromberg J.

Breast Cancer Res. 2010;12(5):R80. doi: 10.1186/bcr2725. Epub 2010 Oct 7.

6.

Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.

Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ, Cheng AL.

Clin Cancer Res. 2010 Nov 1;16(21):5189-99. doi: 10.1158/1078-0432.CCR-09-3389. Epub 2010 Sep 30.

7.

Drug resistance in metastatic castration-resistant prostate cancer.

Seruga B, Ocana A, Tannock IF.

Nat Rev Clin Oncol. 2011 Jan;8(1):12-23. doi: 10.1038/nrclinonc.2010.136. Epub 2010 Sep 21. Review.

PMID:
20859283
8.

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA.

Sci Signal. 2010 Sep 21;3(140):ra67. doi: 10.1126/scisignal.2001083.

9.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A.

N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

10.

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40. doi: 10.1073/pnas.1009472107. Epub 2010 Aug 16.

11.

Mutational status of myeloproliferative neoplasms.

Rumi E, Elena C, Passamonti F.

Crit Rev Eukaryot Gene Expr. 2010;20(1):61-76. Review.

PMID:
20528738
12.

Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

Jarnicki A, Putoczki T, Ernst M.

Cell Div. 2010 May 17;5:14. doi: 10.1186/1747-1028-5-14.

13.

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.

Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ, Kim TY.

Mol Carcinog. 2010 Apr;49(4):353-62. doi: 10.1002/mc.20607.

PMID:
20358631
14.

The landscape of somatic copy-number alteration across human cancers.

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.

Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.

15.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S.

Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3.

16.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M.

Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015.

17.

STATs in cancer inflammation and immunity: a leading role for STAT3.

Yu H, Pardoll D, Jove R.

Nat Rev Cancer. 2009 Nov;9(11):798-809. doi: 10.1038/nrc2734. Review.

18.

Amplification of chromosomal segment 4q12 in non-small cell lung cancer.

Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M.

Cancer Biol Ther. 2009 Nov;8(21):2042-50. Epub 2009 Nov 7.

19.

Environment-mediated drug resistance: a major contributor to minimal residual disease.

Meads MB, Gatenby RA, Dalton WS.

Nat Rev Cancer. 2009 Sep;9(9):665-74. doi: 10.1038/nrc2714. Epub 2009 Aug 20. Review.

PMID:
19693095
20.

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.

Clin Cancer Res. 2009 Aug 15;15(16):5267-73. doi: 10.1158/1078-0432.CCR-09-0888. Epub 2009 Aug 11.

Supplemental Content

Support Center